Anti–SARS-CoV-2 RBD IgG levels before and after COVID-19 vaccination (all vaccine). The anti–SARS-CoV-2 RBD IgG levels in patients in CMT and non-CMT treatment groups were zero at baseline. At 4 weeks after two-dose vaccination, the anti–SARS-CoV-2 RBD IgG levels in patients receiving CMT were 26 U/mL and 267 U/mL in non-CMT treatment (P < .001). CMT, chemotherapy; IgG, immunoglobulin G; IQR, interquartile range; non-CMT, nonchemotherapy; RBD, receptor-binding domain.